Imagine being a Big Pharma or huge investment company (Blackrock/Blackstone/Blacksmith was referenced once - something with black in it) and seeing this announcement.
You likely already had some internal research on this drug that kept it on your acquisition radar/watch list. It flags as a possible treatment across a range of ASD's and non-ASD neurodevelopmental conditions, and you are simply waiting for a confirmation of same following the results of the P3 trial in PMS - I am running with the logic that if it is good in one, it will likely be good in others based on mouse model replication in patients etc etc.
Yesterday's release of information about genetic testing for PMS and increased prevalence would likely be on the radar and make this drug more interesting, given the potential increase in patients.
Now the same drug that you have on your watchlist opens up an entirely new avenue of treatment possibilities that are considered neurodevelopmental (according to Google) but in actuality suggest that there are options for treatment in non-neurodevelopmental conditions.
If it was not already at the top of the watchlist for most interested parties, I think that this information would give serious pause for thought.
Side note - the timing and nature of this is fascinating as well. Another genetically based neuro-developmental condition would likely have moved the needle (not just the SP needle but the interest needle) slightly. I think the fact that this is neurodevelopmental (but not in the same way as our current genetically based conditions) stands to move the needle significantly in the minds of interested parties. JMHO.
NEU Price at posting:
$12.10 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)